echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > A new drug is expected to be used to treat diabetic retinal lesions

    A new drug is expected to be used to treat diabetic retinal lesions

    • Last Update: 2020-12-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    an international team of researchers has announced the development of a new drug that can be used to treat diabetic retinal lesions, and in mouse trials, promising new options for treating human diabetic retinal lesions.
    diabetes retinal lesions are a common complication of diabetes and the main cause of diabetes blindness.According to jennifer Gamble,
    's research leader and a professor at the Centennial Institute of Australia, diabetic retinal lesions are mainly caused by damage to the blood-retinal barrier, the integrity of which depends on the tightness of the connections between capillary endoblast cells, which can cause blood to seep out of the retinal capillaries to form lesions if the gap between endoblast cells is too large or damaged.
    drug developed by Gamble and others is called CD5-2. Studies have found that the drug repairs the blood-retina barrier and reduces blood vessel leakage. The effectiveness of the drug has been tested in mice and the results are published in the German journal Diabetes.
    drug can be used alone or in combination with other existing therapies, promising to better treat diabetic retinal lesions, the researchers said in a statement. They are currently promoting clinical trials. (Source: Xinhua News Agency)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.